This is in line with a report showing that the anti-inflammatory role of IL-37 contributes to the suppression of chronic inflammation, particularly among patients with non-alcoholic fatty liver disease (NAFLD), and subsequently reduces the risk of malignancy (56). Here, IL37 is linked to metabolic dysfunction-associated steatotic liver disease.